183 related articles for article (PubMed ID: 32882002)
1. Allogeneic hematopoietic cell transplantation after prior targeted therapy for high-risk chronic lymphocytic leukemia.
Kim HT; Shaughnessy CJ; Rai SC; Reynolds C; Ho VT; Cutler C; Koreth J; Gooptu M; Romee R; Nikiforow S; Armand P; Alyea EP; Antin JH; Wu CJ; Soiffer RJ; Ritz J; Brown JR
Blood Adv; 2020 Sep; 4(17):4113-4123. PubMed ID: 32882002
[TBL] [Abstract][Full Text] [Related]
2. Allogeneic stem cell transplantation for chronic lymphocytic leukemia in the era of novel agents.
Roeker LE; Dreger P; Brown JR; Lahoud OB; Eyre TA; Brander DM; Skarbnik A; Coombs CC; Kim HT; Davids M; Manchini ST; George G; Shah N; Voorhees TJ; Orchard KH; Walter HS; Arumainathan AK; Sitlinger A; Park JH; Geyer MB; Zelenetz AD; Sauter CS; Giralt SA; Perales MA; Mato AR
Blood Adv; 2020 Aug; 4(16):3977-3989. PubMed ID: 32841336
[TBL] [Abstract][Full Text] [Related]
3. Baseline Characteristics Predicting Very Good Outcome of Allogeneic Hematopoietic Cell Transplantation in Young Patients With High Cytogenetic Risk Chronic Lymphocytic Leukemia - A Retrospective Analysis From the Chronic Malignancies Working Party of the EBMT.
van Gelder M; Ziagkos D; de Wreede L; van Biezen A; Dreger P; Gramatzki M; Stelljes M; Andersen NS; Schaap N; Vitek A; Beelen D; Lindström V; Finke J; Passweg J; Eder M; Machaczka M; Delgado J; Krüger W; Raida L; Socié G; Jindra P; Afanasyev B; Wagner E; Chalandon Y; Henseler A; Schoenland S; Kröger N; Schetelig J;
Clin Lymphoma Myeloma Leuk; 2017 Oct; 17(10):667-675.e2. PubMed ID: 28694085
[TBL] [Abstract][Full Text] [Related]
4. Donor Killer Cell Immunoglobulin-Like Receptor Genotype Does Not Improve Graft-versus-Leukemia Responses in Chronic Lymphocytic Leukemia after Unrelated Donor Transplant: A Center for International Blood and Marrow Transplant Research Analysis.
Bachanova V; Weisdorf DJ; Wang T; Marsh SGE; Cereb N; Haagenson MD; Spellman SR; Lee SJ; Guethlein LA; Parham P; Miller JS; Cooley SA
Biol Blood Marrow Transplant; 2019 May; 25(5):949-954. PubMed ID: 30594542
[TBL] [Abstract][Full Text] [Related]
5. Presalvage International Staging System Stage and Other Important Outcome Associations in CD34
Bryant AR; Hilden P; Giralt S; Chung DJ; Maloy M; Landau H; Landgren O; Scordo M; Shah G; Smith EL; O'Reilly RJ; Perales MA; Koehne G
Biol Blood Marrow Transplant; 2020 Jan; 26(1):58-65. PubMed ID: 31493537
[TBL] [Abstract][Full Text] [Related]
6. High incidence of chronic graft-versus-host disease after myeloablative allogeneic stem cell transplantation for chronic lymphocytic leukemia in Sweden: graft-versus-leukemia effect protects against relapse.
Machaczka M; Johansson JE; Remberger M; Hallböök H; Lazarevic VLj; Wahlin BE; Omar H; Wahlin A; Juliusson G; Kimby E; Hägglund H
Med Oncol; 2013 Dec; 30(4):762. PubMed ID: 24214180
[TBL] [Abstract][Full Text] [Related]
7. Ibrutinib for bridging to allogeneic hematopoietic cell transplantation in patients with chronic lymphocytic leukemia or mantle cell lymphoma: a study by the EBMT Chronic Malignancies and Lymphoma Working Parties.
Dreger P; Michallet M; Bosman P; Dietrich S; Sobh M; Boumendil A; Nagler A; Scheid C; Cornelissen J; Niederwieser D; Müller L; Vandenberghe E; Scortechini I; Schoemans H; Andersen NS; Finke J; Russo D; Ljungman P; Passweg J; van Gelder M; Durakovic N; Labussiere-Wallet H; Berg T; Wulf G; Bethge W; Bunjes D; Stilgenbauer S; Canepari ME; Schaap M; Fox CP; Kröger N; Montoto S; Schetelig J
Bone Marrow Transplant; 2019 Jan; 54(1):44-52. PubMed ID: 29728701
[TBL] [Abstract][Full Text] [Related]
8. Allogeneic hematopoietic stem cell transplantation for poor-risk CLL: dissecting immune-modulating strategies for disease eradication and treatment of relapse.
Hahn M; Böttcher S; Dietrich S; Hegenbart U; Rieger M; Stadtherr P; Bondong A; Schulz R; Ritgen M; Schmitt T; Tran TH; Görner M; Herth I; Luft T; Schönland S; Witzens-Harig M; Zenz T; Kneba M; Ho AD; Dreger P
Bone Marrow Transplant; 2015 Oct; 50(10):1279-85. PubMed ID: 26146810
[TBL] [Abstract][Full Text] [Related]
9. Early versus late preemptive allogeneic hematopoietic cell transplantation for relapsed or refractory acute myeloid leukemia.
Chen GL; Liu H; Zhang Y; Thomas J; Ross M; Wang ES; Block AW; Sait S; Deeb G; Wallace P; Wetzler M; Hahn T; McCarthy PL
Biol Blood Marrow Transplant; 2014 Sep; 20(9):1369-74. PubMed ID: 24867777
[TBL] [Abstract][Full Text] [Related]
10. Combined Haploidentical and Umbilical Cord Blood Allogeneic Stem Cell Transplantation for High-Risk Lymphoma and Chronic Lymphoblastic Leukemia.
Hsu J; Artz A; Mayer SA; Guarner D; Bishop MR; Reich-Slotky R; Smith SM; Greenberg J; Kline J; Ferrante R; Phillips AA; Gergis U; Liu H; Stock W; Cushing M; Shore TB; van Besien K
Biol Blood Marrow Transplant; 2018 Feb; 24(2):359-365. PubMed ID: 29128555
[TBL] [Abstract][Full Text] [Related]
11. Genomic aberrations deletion 11q and deletion 17p independently predict for worse progression-free and overall survival after allogeneic hematopoietic cell transplantation for chronic lymphocytic leukemia.
Chavez JC; Kharfan-Dabaja MA; Kim J; Yue B; Dalia S; Pinilla-Ibarz J; Anasetti C; Locke FL
Leuk Res; 2014 Oct; 38(10):1165-72. PubMed ID: 24889511
[TBL] [Abstract][Full Text] [Related]
12. Allogeneic transplantation for high-risk chronic lymphocytic leukemia-a summary of a 16-year experience.
Helbig G; Spałek A; Wieczorkiewicz-Kabut A; Markiewicz M; Kopera M; Zielińska P; Woźniczka K; Kopińska A; Grygoruk-Wiśniowska I; Koclęga A
Ann Hematol; 2019 Jun; 98(6):1477-1483. PubMed ID: 30919074
[TBL] [Abstract][Full Text] [Related]
13. Post-transplantation cyclophosphamide reduces the incidence of acute graft-versus-host disease in patients with acute myeloid leukemia/myelodysplastic syndromes who receive immune checkpoint inhibitors after allogeneic hematopoietic stem cell transplantation.
Saberian C; Abdel-Wahab N; Abudayyeh A; Rafei H; Joseph J; Rondon G; Whited L; Gruschkus S; Fa'ak F; Daher M; Knape C; Safa H; Shoukier M; Suarez-Almazor ME; Marcotulli M; Ludford K; Gulbis AM; Konopleva M; Ohanian M; Ravandi F; Garcia-Manero G; Oran B; Popat UR; Mehta R; Alousi AM; Daver N; Champlin R; Diab A; Al-Atrash G
J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33637601
[TBL] [Abstract][Full Text] [Related]
14. Allogeneic hematopoietic stem-cell transplantation for chronic lymphocytic leukemia with 17p deletion: a retrospective European Group for Blood and Marrow Transplantation analysis.
Schetelig J; van Biezen A; Brand R; Caballero D; Martino R; Itala M; García-Marco JA; Volin L; Schmitz N; Schwerdtfeger R; Ganser A; Onida F; Mohr B; Stilgenbauer S; Bornhäuser M; de Witte T; Dreger P
J Clin Oncol; 2008 Nov; 26(31):5094-100. PubMed ID: 18711173
[TBL] [Abstract][Full Text] [Related]
15. Prognostic Score and Cytogenetic Risk Classification for Chronic Lymphocytic Leukemia Patients: Center for International Blood and Marrow Transplant Research Report.
Kim HT; Ahn KW; Hu ZH; Davids MS; Volpe VO; Antin JH; Sorror ML; Shadman M; Press O; Pidala J; Hogan W; Negrin R; Devine S; Uberti J; Agura E; Nash R; Mehta J; McGuirk J; Forman S; Langston A; Giralt SA; Perales MA; Battiwalla M; Hale GA; Gale RP; Marks DI; Hamadani M; Ganguly S; Bacher U; Lazarus H; Reshef R; Hildebrandt GC; Inamoto Y; Cahn JY; Solh M; Kharfan-Dabaja MA; Ghosh N; Saad A; Aljurf M; Schouten HC; Hill BT; Pawarode A; Kindwall-Keller T; Saba N; Copelan EA; Nathan S; Beitinjaneh A; Savani BN; Cerny J; Grunwald MR; Yared J; Wirk BM; Nishihori T; Chhabra S; Olsson RF; Bashey A; Gergis U; Popat U; Sobecks R; Alyea E; Saber W; Brown JR
Clin Cancer Res; 2019 Aug; 25(16):5143-5155. PubMed ID: 31253630
[TBL] [Abstract][Full Text] [Related]
16. Treatment-related mortality and graft-versus-leukemia activity after allogeneic stem cell transplantation for chronic lymphocytic leukemia using intensity-reduced conditioning.
Dreger P; Brand R; Hansz J; Milligan D; Corradini P; Finke J; Deliliers GL; Martino R; Russell N; Van Biezen A; Michallet M; Niederwieser D;
Leukemia; 2003 May; 17(5):841-8. PubMed ID: 12750695
[TBL] [Abstract][Full Text] [Related]
17. Idelalisib treatment prior to allogeneic stem cell transplantation for patients with chronic lymphocytic leukemia: a report from the EBMT chronic malignancies working party.
Schetelig J; Chevallier P; van Gelder M; Hoek J; Hermine O; Chakraverty R; Browne P; Milpied N; Malagola M; Socié G; Delgado J; Deconinck E; Damaj G; Maury S; Beelen D; Quoc SN; Shankara P; Brecht A; Mayer J; Hunault-Berger M; Bittenbring J; Thieblemont C; Lepretre S; Baldauf H; de Wreede LC; Tournilhac O; Yakoub-Agha I; Kröger N; Dreger P
Bone Marrow Transplant; 2021 Mar; 56(3):605-613. PubMed ID: 33004942
[TBL] [Abstract][Full Text] [Related]
18. Risk factors for treatment failure after allogeneic transplantation of patients with CLL: a report from the European Society for Blood and Marrow Transplantation.
Schetelig J; de Wreede LC; van Gelder M; Andersen NS; Moreno C; Vitek A; Karas M; Michallet M; Machaczka M; Gramatzki M; Beelen D; Finke J; Delgado J; Volin L; Passweg J; Dreger P; Henseler A; van Biezen A; Bornhäuser M; Schönland SO; Kröger N
Bone Marrow Transplant; 2017 Apr; 52(4):552-560. PubMed ID: 28112746
[TBL] [Abstract][Full Text] [Related]
19. Progressive chronic lymphocytic leukemia after allogeneic hematopoietic cell transplantation.
Jitawatanarat P; Desai A; Sharda P; Liu H; Ross M; Hernandez-Llizaliturri FJ; McCarthy PL; Chen GL
J Natl Compr Canc Netw; 2012 Oct; 10(10):1203-6. PubMed ID: 23054874
[TBL] [Abstract][Full Text] [Related]
20. Low-Dose Antithymocyte Globulin for Graft-versus-Host-Disease Prophylaxis in Matched Unrelated Allogeneic Hematopoietic Stem Cell Transplantation.
Bryant A; Mallick R; Huebsch L; Allan D; Atkins H; Anstee G; Sabloff M; Scrivens N; Maze D; Bredeson C; Kekre N
Biol Blood Marrow Transplant; 2017 Dec; 23(12):2096-2101. PubMed ID: 28821454
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
